Based on the team's discovery that an enzyme called CD38, implicated in aging metabolism, is elevated in scleroderma and underlies fibrosis, they created an antibody engineered to selectively ...

An enzyme called CD38 has been discovered by researchers that is responsible for the decrease in nicotinamide adenine dinucleotide (NAD) during aging, a process that is associated with age-related ...

This article demonstrates how the Transcreener ADPR Assay will provide a reliable and robust tool for the discovery of CD38 and PARG inhibitors.

Y-mAbs presented preclinical PK data for CD38-SADA at the 2025 AACR Annual Meeting, supporting its cancer treatment development.

Genmab A/S (Nasdaq: GMAB) said on Monday that Johnson & Johnson (J&J) has decided not to exercise its option to obtain a worldwide license for the development, manufacturing, and commercialization ...

CD38 is an enzyme with NAD-depleting and intracellular signaling activity expressed on the cell surface, in intracellular compartments and in mitochondria, and is linked to inflammatory and autoimmune ...

To uncover the molecular mechanisms regulating ovarian NAD+ loss, first the researchers began by adding another piece of the puzzle: CD38, an enzyme known to be one of the main culprits in ...

As an extracellular enzyme, CD38 can then catalyze the cleavage of NAD+ into cyclic adenosine diphosphate ribose (cADPR).

Antibody targeting CD38 enzyme shows positive impact in treating systemic sclerosis by Valerie Goodwin, University of Michigan Editors' notes ...

Based on the team’s discovery that an enzyme called CD38, implicated in aging metabolism, is elevated in scleroderma and underlies fibrosis, they created an antibody engineered to selectively ...